abstract: Embryo DNA fingerprinting represents an important tool for tracking embryo-specific outcomes after multiple embryo transfer during IVF. The situation in which two embryos are transferred and only one implants represents a unique opportunity for the most wellcontrolled validation of markers capable of identifying competent and incompetent embryos. Specifically, this design eliminates all patientrelated variables from the comparison of embryos with or without reproductive potential. However, in order to determine which embryo implanted, the investigator must wait until newborn DNA is available upon delivery. This study validates a non-invasive cell-free fetal DNA fingerprinting method that reduces the time to identify which embryo implanted by 31 weeks. Thirty-four patients were studied to determine if fingerprinting of fetal DNA extracted from maternal plasma at nine gestational weeks concurred with the buccal DNA results obtained from the newborn after delivery. This validation required single nucleotide polymorphism profiles on each couples' preimplantation embryos, cell-free fetal DNA from maternal plasma at 9 weeks gestation, and newborn DNA obtained from buccal swabs after delivery. The predictions from fetal DNA-based embryo tracking and gender assignments made at 9 weeks gestation were 100% consistent with standardized methods of assessment performed after term delivery. This study demonstrates the first validated fetal DNA fingerprinting method which predicts both gender and which embryo implanted at 9 weeks gestation following multiple embryo transfer.
Introduction
DNA fingerprinting to identify which embryos implant after multiple embryo transfer allows for elimination of all non-embryonic variables from studies designed to identify and validate markers of embryonic reproductive potential and therefore represents a powerful investigative tool. We recently developed a robust single nucleotide polymorphism (SNP) microarray-based DNA fingerprinting technology capable of clearly discriminating IVF derived sibling human embryos from either a first polar body (Treff et al., 2010) or a single blastomere (Treff et al., 2009) . While the power and advantages of DNA fingerprinting are intuitive and obvious, the application has the disadvantage of needing to wait until DNA is available from the conceptus to obtain an interpretable result. Since obtaining fetal DNA from amniocentesis or chorionic villus sampling is not routine, DNA from newborn buccal swabs currently represents the most typical and least invasive method for obtaining DNA for fingerprinting. As a result, studies utilizing DNA fingerprinting are subject to a delay of 38 weeks. This results in a substantial delay in determining whether an embryonic marker of interest is clinically relevant and truly predictive of reproductive competence.
The presence of cell-free fetal DNA in maternal circulation in pregnant woman has been well established since its original description in 1997 (Lo et al., 1997) , and may represent a source for early recovery of fetal DNA to identify which embryo implanted following IVF. More recent studies indicate that fetal DNA can be detected in maternal circulation as early as 5 weeks gestation (Birch et al., 2005) . Unlike fetal cells which can remain in maternal circulation for extended periods of time, cell-free fetal DNA may be cleared from the maternal circulation within minutes after delivery (Lo et al., 1999) , thus reducing the likelihood of false positive results due to carryover from a previous pregnancy. While it has been estimated that cell-free fetal DNA content within maternal circulation represents only 3% of the total free DNA obtained from plasma during early pregnancy (Lo et al., 1998a, b) , fetal DNA molecules are smaller than the corresponding maternal DNA fragments (Chan et al., 2004) . This difference provides an opportunity for fetal DNA enrichment by purification of the lower molecular weight fraction of cell-free DNA from maternal plasma (Li et al., 2004) .
Most of the previous work involving analysis of cell-free fetal DNA has been aimed at the development of non-invasive prenatal diagnostics, such as gender determination for sex-linked disorders (Costa et al., 2002; Cremonesi et al., 2004; Birch et al., 2005; Picchiassi et al., 2008) , or diagnosis of fetal RhD status (Lo et al., 1998a, b; Singleton et al., 2000; van der Schoot et al., 2003; Clausen et al., 2005) , and single gene disorders (Amicucci et al., 2000; Chiu et al., 2002; Gonzalez-Gonzalez et al., 2002) . No prior studies have evaluated the ability to track which embryos implanted after multiple embryo transfer following IVF. SNP microarray-based DNA fingerprinting of cell-free fetal DNA, in combination with identification of informative SNPs through profiling of parental DNA, might be used to track embryo implantation early in established pregnancies. Validation of embryo tracking from maternal blood could be accomplished by comparing the cell-free fetal DNA-based prediction of which embryo implanted to a standard method of prediction made using newborn buccal DNA (Treff et al., 2009 ). We performed this comparison analysis in order to demonstrate the validity of a fetal DNA fingerprinting method that uses maternal plasma-derived cell-free fetal DNA obtained at 9 weeks gestation. This technique should reduce the time to confirm which embryo implanted by 31 weeks.
Materials and Methods

Experimental design
This study sought to validate the use of cell-free fetal DNA obtained from maternal circulation at 9 weeks gestation in two ways. In phase I, gender prediction using cell-free fetal DNA at 9 weeks gestation was compared with observations made by ultrasound sonography (USS) during pregnancy and by physical manifestation upon delivery. This validation was useful to establish the capability of fetal DNA enrichment technology.
Phase II involved comparison of cell-free fetal DNA-based identification of which embryos implanted with a standardized buccal DNA-based identification method (Treff et al., 2009) . Both methods involved comparison of SNP genotyping microarray profiles with profiles obtained from embryo biopsy DNA. This validation step was useful to establish the predictive value of fetal DNA-based embryo tracking at 9 weeks gestation.
Patients
Thirty-four patients with an ongoing pregnancy and subsequent newborn delivery resulting from IVF were included in this study. Patients that consented to have blood drawn after becoming pregnant and that successfully became pregnant after IVF embryo transfer were included in the present study. Patients gave consent prior to their IVF cycle. The consent form included description of the study-related interventions (embryo biopsy, patient and partner blood draws and newborn buccal swabs). All materials were obtained under Institutional Review Board approval and analyzed with patient consent.
Phase I: consistency of gender prediction
Phase I of this study involved enrichment of fetal DNA from 4 ml of maternal peripheral whole blood (obtained at 9 weeks gestation) using the QIAamp Virus Kit (QIAgen Inc., Valencia, CA, USA) as described previously (Legler et al., 2008) . Ten microliters of enriched cell-free fetal DNA was processed using the TaqMan PreAmp Master Mix Kit as recommended by the supplier (Applied Biosystems Inc., Foster City, CA, USA), except that cDNA synthesis was not necessary since the initial sample was cell-free fetal DNA and not RNA. TaqMan assays used in the primer pool were predesigned for the SRY (assay identification numbers; Hs00243216_s1 and Hs00976796_s1), CYorf15B (Hs00295373_s1), NLGN4Y (Hs01034378_s1) and XKRY (Hs00245052_s1) genes located on the Y chromosome (Applied Biosystems Inc.). Quantitative real-time (q) PCR analysis was then performed using individual 5 ml reactions with each of the same assays above, Gene Expression Master Mix, a 7900HT instrument and SDS 2.3 software, all obtained from and as recommended by the same manufacturer (Applied Biosystems Inc.). Samples with amplification of any of the five Y chromosome assays were interpreted as male. Samples with no amplification were interpreted as female. Results of cell-free fetal DNA-based gender predictions were compared with the gender observed by ultrasound and after delivery, which was unknown at the time of cell-free fetal DNA analysis (blinded). Ultrasounds were performed by an obstetrics and gynecology physician for each patient at 20 weeks into the pregnancy.
Phase II: consistency of embryo tracking
Phase II of this study involved 17 patients who underwent SNP microarraybased analysis of preimplantation stage IVF embryos for DNA fingerprinting (Treff et al., 2009) . Genomic DNA was isolated from maternal and paternal whole blood prior to embryo transfer, and newborn buccal swabs after delivery, using the QIAamp DNeasy Tissue kit as recommended for cell cultures (QIAgen Inc.). Cell-free fetal DNA was obtained as described above for phase I. Whole genome amplification (WGA) was applied to the cell-free fetal DNA using the GenomePlex WGA4 Kit and purified using GenElute PCR purification columns as recommended by the supplier (Sigma Aldrich, St. Louis, MO, USA). Embryo biopsy was performed at the cleavage or blastocyst stage as previously described (Treff at al., 2010) .
Two hundred and fifty nanograms of (i) parental genomic DNA, (ii) embryo biopsy WGA DNA, (iii) cell-free fetal WGA DNA and (iv) newborn buccal genomic DNA were processed using NspI 262K SNP microarrays as recommended by the supplier (Affymetrix Inc., Santa Clara, CA, USA). The dynamic model mapping algorithm (Di et al., 2005) was used to assign a confidence score measuring the reliability of each genotype call made (GTYPE version 4.1, Affymetrix Inc.). SNP calls were exported as a text file and imported into Microsoft Excel (Microsoft Inc., Redmond, WA, USA) to select 'informative' SNPs for comparison analyses. SNPs that were heterozygous in either or both the maternal and paternal DNA, and homozygous opposite in a specific combination of two sibling embryos, were considered informative for that specific combination of two embryos.
Analysis involved determining the percent similarity of informative SNPs for each of the two embryos with the cell-free fetal DNA sample. The percent similarity was determined by comparing each individual SNP genotype in the two samples under evaluation (one of the two embryos and the cell-free fetal DNA sample). The number of SNPs with the same genotype was divided by the total number of SNPs compared between the two samples resulting in a percent similarity for the embryo and cell-free fetal DNA. The same procedure was then conducted on the second embryo in the set of two embryos being evaluated. All possible combinations of two embryos were analyzed in a similar manner. Each individual embryo was then given an average percent similarity from all possible two embryo analyses. The embryo with the highest average percent similarity to the cell-free fetal DNA was given the designation of implanted and the Tracking embryo implantation remaining embryos were designated as non-implanted (predicted siblings). Only cases where biopsies from at least two embryos that were arrested or cryopreserved (non-transferred) were included. These non-transferred embryos provided a positive control for known sibling embryos. This overall process was performed independently for each patient without knowledge of which embryos were transferred and which of the transferred embryos implanted (blinded). The number of embryos that implanted was known at the time of analysis so that cell-free fetal DNA analysis from patients with singletons or twins could be performed accordingly. Once the cell-free fetal DNA-based predictions of which embryo(s) implanted were made, results of the buccal DNA-based predictions (Treff et al., 2009) were revealed and compared for consistency.
The microarray data described in this study have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE26404 (http://www.ncbi.nlm.nih.gov/geo).
Statistics
The mean cell-free fetal DNA informative SNP percent similarities with non-transferred known sibling embryos, transferred sibling embryos and transferred implanted embryos were compared using a one-way analysis of variance.
Results
Phase I: consistency of gender prediction
Thirteen of the 34 cell-free fetal DNA samples were positive for at least one of the five Y chromosome assays. Twenty-one samples were negative for all Y chromosome assays. Newborn gender was confirmed by USS and upon delivery and compared with the cell-free fetal DNA predicted gender. Eleven of the 13 Y chromosome positive cell-free fetal DNA samples were found to have come from patients delivering a singleton male. Two of the 13 Y chromosome positive samples were from patients who delivered one female and one male (twins). The 21 samples that were negative for all Y chromosome assays were found to have come from patients delivering singleton (n ¼ 13) or twin (n ¼ 8) females. Therefore, the predictive value of cell-free fetal DNA analysis for gender was 100% (n ¼ 34). This result indicated that the fetal DNA enrichment process might be amenable to SNP microarray-based embryo tracking.
Phase II: consistency of embryo tracking
An average WGA yield of 10.9 + 2.7 mg of DNA was obtained from the 17 cell-free fetal DNA samples and was sufficient for proceeding with microarray-based SNP genotyping in all cases. Two single embryo transfer patients, with available non-transferred embryo biopsies, served as a positive control (Fig. 1A, patient # 8 and 10) . The embryos predicted to have implanted by cell-free fetal DNA analysis were indeed the embryos that were transferred. The average similarities of these embryos to the cell-free fetal DNA were 54% (patient #8) and 58% (patient #10), while the remaining nontransferred embryos ranged from 38 to 48% similarity. Standardized buccal DNA-based predictions of which embryos implanted (Treff et al., 2009) were also consistent with which embryos were transferred. Four double embryo transfers that led to delivery of twins (Fig. 1A , patient #9 and 14-16) provided another control set from which consistent findings were also obtained.
The remaining 11 cases (Fig. 1A , patient #1 -7, 11 -13 and 17) involved a double embryo transfer resulting in a singleton implantation and delivery. The transferred embryos predicted to have implanted Figure 1 (A) Results of comparison of enriched cell-free fetal DNA with transferred self, transferred sibling (sib) and non-transferred sib control embryos, in each of the 17 patients evaluated. Transferred self and sib designations were determined by observations made after delivery. Nontransferred sib designation was based upon the fact that these embryos were not transferred but were derived from the same patient in the same IVF treatment cycle. (B) Overall percent similarities of cell-free fetal DNA with self (implanted) and transferred and non-transferred sibling embryos with +1 standard deviation (error bars). A significant difference (P , 0.0001) was observed between data indicated with an 'a' and data indicated with a 'b' above each bar.
(n ¼ 11) were 55 + 2% similar to the corresponding cell-free fetal DNA. The transferred embryos predicted to be siblings (n ¼ 11) were 44 + 4% similar to the cell-free fetal DNA. The non-transferred embryos (sibling embryo positive controls, n ¼ 64) were also 45 + 4% similar to cell-free fetal DNA. In addition, the newborn buccal DNAbased predictions of which embryo implanted were 100% consistent with the cell-free fetal DNA-based predictions (Fig. 1A) . Finally, the overall percent similarity of cell-free fetal DNA with implanted embryos was significantly higher (P , 0.0001) than the similarity to sibling embryos (Fig. 1B) .
Discussion
Our results support the hypothesis that enriched cell-free fetal DNA can reliably be used to predict fetal gender and identify which embryo implanted at only 9 weeks gestation after multiple embryo transfer. The results obtained from the maternal plasma-derived sample were 100% consistent with observations made from newborn genomic DNA after delivery. While previous studies have established the ability to determine fetal gender, this is the first study to evaluate more than two loci within the Y chromosome, and as a result, to demonstrate 100% sensitivity and specificity for gender prediction as early as 9 weeks gestation. Although not the primary application, this technology may be useful in early and accurate assessment of fetal gender in pregnancies from both natural and IVF derived conception.
It should also be noted that this technology is not the same as identifying which embryo implanted by using DNA derived directly from the conceptus (Treff et al., 2009 (Treff et al., , 2010 . Since there is a considerable amount of maternal DNA present within the enriched cell-free fetal DNA sample, it is far more difficult to distinguish which embryo implanted then if pure conceptus derived DNA was available. Despite the challenge faced by an enormous background of contaminating maternal DNA, the technology developed here is sufficient to identify which embryo implanted following enrichment of fetal DNA from maternal circulation. With the recent and exciting advancements made through the use of next generation sequencing-based methodologies for fetal DNA genotyping in maternal circulation (Lo et al., 2010) , whether the technique described in the present study could be put to similar use might be questioned. However, the method described here was not intended to diagnose individual fetal-specific genotypes. As such, the reliability of the present method for genotyping the fetus at a specific locus was not investigated and is likely not of sufficient accuracy to be applied in a fashion similar to that previously reported (Lo et al., 2010) . However, the cost of methods reported by Lo et al. may not be necessary for the purpose of embryo tracking which was the specific aim of the method developed and validated in the present study.
Indeed, there are many benefits of the availability of this method with respect to the alternative embryo tracking technique which typically requires obtaining newborn buccal DNA upon delivery (Treff et al., 2009 (Treff et al., , 2010 . Since many IVF programs discharge patients at 9 weeks of gestation, the ability to obtain maternal blood during the final visit to the clinic will increase the rate of participation, and ultimately, the ability to identify which embryo implanted. Secondly, drawing blood from maternal circulation at the clinic is less expensive and better controlled than the process of obtaining buccal DNA collections through the mail. Finally, and perhaps the most important advantage, is the ability to non-invasively identify which embryo(s) implanted 31 weeks prior to conventional newborn buccal DNA methods.
This new tool should allow and encourage investigators to perform higher quality and more precise studies regarding laboratory conditions or methods of embryo selection. While traditional experimental design paradigms may provide meaningful results, the ability to do paired analyses will produce higher quality, less costly and more rapid results. One potential drawback to the incorporation of DNA fingerprinting is the necessity of either a polar body or embryo biopsy. It will remain the responsibility of the principal investigator, the Institutional Review Board, and the patient to determine if the information to be gained is of sufficient importance to justify the invasiveness of the procedure. However, given the critical issues surrounding optimization of in vitro culture and indentifying which embryos are competent, there are likely many important studies which will benefit from the improved precision and rapid results afforded by this procedure.
